Details for Patent: 8,822,430
✉ Email this page to a colleague
Which drugs does patent 8,822,430 protect, and when does it expire?
Patent 8,822,430 protects HARVONI and is included in two NDAs.
Protection for HARVONI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and thirty-nine patent family members in thirty-nine countries.
Summary for Patent: 8,822,430
| Title: | Antiviral compounds |
| Abstract: | The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. |
| Inventor(s): | Bacon; Elizabeth M. (Burlingame, CA), Canales; Eda (San Mateo, CA), Cho; Aesop (Mountain View, CA), Cottell; Jeromy J. (Redwood City, CA), Desai; Manoj C. (Pleasant Hill, CA), Graupe; Michael (Pacifica, CA), Guo; Hongyan (San Mateo, CA), Halcomb; Randall L. (Foster City, CA), Kato; Darryl (San Francisco, CA), Kim; Choung U. (San Carlos, CA), Kirschberg; Thorsten A. (Redwood City, CA), Krygowski; Evan S. (Belmont, CA), Lazerwith; Scott E. (San Francisco, CA), Link; John O. (San Francisco, CA), Liu; Hongtao (Foster City, CA), Liu; Qi (Union City, CA), Mackman; Richard L. (Millbrae, CA), Mitchell; Michael L. (Heyward, CA), Parrish; Jay P. (Redwood City, CA), Pyun; Hyung-Jung (Fremont, CA), Saugier; Joseph H. (Livermore, CA), Schroeder; Scott D. (Foster City, CA), Sun; Jianyu (Surrey, CA), Taylor; James G. (San Mateo, CA), Trenkle; James D. (Oakland, CA), Tse; Winston C. (Redwood City, CA), Vivian; Randall W. (San Mateo, CA), Watkins; William J. (Saratoga, CA), Xu; Lianhong (Palo Alto, CA) |
| Assignee: | Gilead Pharmasset LLC (Foster City, CA) |
| Application Number: | 13/956,195 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 8,822,430
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-001 | Aug 28, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-002 | Aug 28, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-002 | Aug 28, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-001 | Oct 10, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,822,430
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2430014 | ⤷ Sign Up | CA 2016 00006 | Denmark | ⤷ Sign Up |
| European Patent Office | 2430014 | ⤷ Sign Up | PA2016002 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2430014 | ⤷ Sign Up | 300796 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2430014 | ⤷ Sign Up | 16C0005 | France | ⤷ Sign Up |
| European Patent Office | 2430014 | ⤷ Sign Up | 232 5001-2016 | Slovakia | ⤷ Sign Up |
| European Patent Office | 2430014 | ⤷ Sign Up | C20160002 00186 | Estonia | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
